Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ticagrelor

FDA-approved product (tablet, oral), marketed as Brilinta, Ticagrelor.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ticagrelor
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Acute myocardial infarction
  • Coronary artery disease
  • Myocardial infarction
  • Peripheral vascular disease
  • Recurrent thrombophlebitis
  • Stroke
  • Thrombotic disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
FDA pharmacologic class
P2Y12 Platelet Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ticagrelor in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ticagrelor with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting

    NCT02330640 · start 2016-01

    Registered record
    Registry ID
    NCT02330640
    Conditions
    Antiplatelet Therapy of Coronary Artery Bypass
    Interventions
    ticagrelor; clopidogrel; asprin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-01
    Completion
    2016-10-01
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntiplatelet Therapy of Coronary Artery Bypass
    Interventionticagrelor; clopidogrel; asprin
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients

    NCT02602444 · start 2015-10

    Registered record
    Registry ID
    NCT02602444
    Conditions
    Myocardial Infarction
    Interventions
    ticagrelor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-10
    Completion
    2017-01
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction
    Interventionticagrelor
    PhaseNot recorded
    Registry statusCompleted

  • Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

    NCT02531165 · start 2015-09

    Registered record
    Registry ID
    NCT02531165
    Conditions
    Acute Myocardial Infarction
    Interventions
    Fentanyl; Morphine; Ticagrelor; Aspirin; Unfractioned Heparin; Primary PCI
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-09
    Completion
    2018-02-06
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myocardial Infarction
    InterventionFentanyl; Morphine; Ticagrelor; Aspirin +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)

    NCT03487406 · start 2015-09

    Registered record
    Registry ID
    NCT03487406
    Conditions
    Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    Ticagrelor; Aspirin; Placebo Aspirin; Placebo Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-09
    Completion
    2017-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease (COPD)
    InterventionTicagrelor; Aspirin; Placebo Aspirin; Placebo Ticagrelor
    PhasePhase 2
    Registry statusCompleted

  • Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

    NCT02291419 · start 2015-07

    Registered record
    Registry ID
    NCT02291419
    Conditions
    Myocardial Injury
    Interventions
    ticagrelor; aspirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-07
    Completion
    2016-06
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Injury
    Interventionticagrelor; aspirin
    PhasePhase 4
    Registry statusTerminated

  • Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI

    NCT02469740 · start 2015-07

    Registered record
    Registry ID
    NCT02469740
    Conditions
    Myocardial Ischemia; Coronary Artery Disease; Endothelial Dysfunction
    Interventions
    Ticagrelor; Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-07
    Completion
    2016-01
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Ischemia; Coronary Artery Disease; Endothelial Dysfunction
    InterventionTicagrelor; Clopidogrel
    PhasePhase 4
    Registry statusCompleted

  • Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet

    NCT02400333 · start 2015-06

    Registered record
    Registry ID
    NCT02400333
    Conditions
    Bioavailability; Healthy Subjects
    Interventions
    Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water; Ticagrelor OD tablet (90 mg single dose) administered without water; Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube; Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-06
    Completion
    2015-07
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioavailability; Healthy Subjects
    InterventionTicagrelor OD tablet (90 mg single dose) administered with 200 ml of water; Ticagrelor OD tablet (90 mg single dose) administered without water; Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube; Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water
    PhasePhase 1
    Registry statusCompleted

  • Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients

    NCT02430493 · start 2015-05-28

    Registered record
    Registry ID
    NCT02430493
    Conditions
    Acute Coronary Syndrome (ACS)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-05-28
    Completion
    2017-03-29
    Enrolment
    1,066

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome (ACS)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

    NCT02227368 · start 2014-10-20

    Registered record
    Registry ID
    NCT02227368
    Conditions
    Peripheral Artery Disease (PAD)
    Interventions
    Ticagrelor; Comparator
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-10-20
    Completion
    2016-05-23
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Artery Disease (PAD)
    InterventionTicagrelor; Comparator
    PhasePhase 2
    Registry statusTerminated

  • A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk

    NCT02044146 · start 2014-09

    Registered record
    Registry ID
    NCT02044146
    Conditions
    Acute Coronary Syndrome; Percutaneous Coronary Intervention
    Interventions
    Ticagrelor, Prasugrel, Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-09
    Completion
    2017-06
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome; Percutaneous Coronary Intervention
    InterventionTicagrelor, Prasugrel, Clopidogrel
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .

    NCT02032303 · start 2014-02

    Registered record
    Registry ID
    NCT02032303
    Conditions
    Acute Coronary Syndrome; Non ST Elevation Myocardial Infarction; ST Elevation Myocardial Infarction; Unstable Angina
    Interventions
    Assessment of coronary flow reserve; Percutaneous Coronary Intervention; Ticagrelor loading; Prasugrel loading
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2014-02
    Completion
    Not recorded
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome; Non ST Elevation Myocardial Infarction; ST Elevation Myocardial Infarction; Unstable Angina
    InterventionAssessment of coronary flow reserve; Percutaneous Coronary Intervention; Ticagrelor loading; Prasugrel loading
    PhasePhase 4
    Registry statusUnknown

  • Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction

    NCT02075125 · start 2014-01

    Registered record
    Registry ID
    NCT02075125
    Conditions
    ST-Segment Elevation Myocardial Infarction
    Interventions
    Prasugrel 60 mg; Ticagrelor 180 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2014-01
    Completion
    2015-04
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionST-Segment Elevation Myocardial Infarction
    InterventionPrasugrel 60 mg; Ticagrelor 180 mg
    PhasePhase 3
    Registry statusTerminated

  • A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

    NCT01611272 · start 2013-04-30

    Registered record
    Registry ID
    NCT01611272
    Conditions
    Acute Coronary Syndromes
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-04-30
    Completion
    2016-07-20
    Enrolment
    3,402

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndromes
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG

    NCT01755520 · start 2013-04-24

    Registered record
    Registry ID
    NCT01755520
    Conditions
    Coronary Artery Disease; Stable Angina; Acute Coronary Syndrome
    Interventions
    Ticagrelor; Aspirin; Placebo - Ticagrelor; Placebo - Aspirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-04-24
    Completion
    2018-05-19
    Enrolment
    1,893

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Stable Angina; Acute Coronary Syndrome
    InterventionTicagrelor; Aspirin; Placebo - Ticagrelor; Placebo - Aspirin
    PhasePhase 3
    Registry statusTerminated

  • In Vitro Interaction Between Ticagrelor and Its Active Metabolite and Their Effects on Salicylic Acid

    NCT01777516 · start 2012-12

    Registered record
    Registry ID
    NCT01777516
    Conditions
    Cardiovascular Diseases
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-12
    Completion
    2013-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted